Insulin Independence after Allotransplantation of Fetal Hematopoietic Stem Cells in Patients with Type 1 Diabetes: a 2-Years Follow-Up

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 834-867-Islet Biology
Bench to Bedside
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-866
Bagher Larijani*1, Farzaneh Abbasi2, Maryam Ghodsi2, Ramin Heshmat2, Mohammad Ebrahimi2, Mohammad Ali Sharifi2 and Mahsa Mohammad Amoli2
1Endo and Metabolism Research Ins, Tehran, Iran, 2Endocrinology and Metabolism Research Institute
Introduction:Cell therapy is considered as one of the most promising superlative potential treatments for type 1 diabetes. In this regard, various strategies including islet transplantation, obtaining beta cells from stem cells as an alternative source of islets, using porcine islets, and beta cell expansion with growth factors have been examined. The aim of this study was to assess the outcome of treatment with fetal hematopoietic stem cells in patients with type 1 diabetes under specific conditions.

Methods: Eighteen patients with type 1 diabetes aged 6-40 years were included in the study. Each patient intravenously  received fetal liver derived hematopoietic stem cells from human legally aborted early fetus aged 6 -12 weeks. The patients had been followed up for 2 years and their plasma glucose as well as HbA1C levels were monitored over this period. This study was approved by the ethical committee of Tehran University of Medical Sciences and Iranian Registry of Clinical Trials

Results: Blood glucose levels gradually decreased within the first day after the treatment in 5/18 patients. Daily insulin requirement of these 5 patients was (0.35-0.70 u/kg/day) before the intervention. 2/5 patients stayed constantly insulin free for 16 and 24 months. In other patients, there were no significant changes in their condition.

Conclusion: In this study, it was observed that fetal hematopoietic stem cell transplantation in patients with type 1 diabetes was successful in diabetes treatment to some extent. Moreover, using no immunosuppressive agents before and after the transplantation according to the low immunogenicity of fetal hematopoietic stem cells can be considered as an advantage to this new therapeutic modality However, further clinical trials with larger number of patients and long term follow- ups would be useful to confirm our results.

Nothing to Disclose: BL, FA, MG, RH, ME, MAS, MM

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm